721,957 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Purchased by Capital World Investors

Capital World Investors bought a new position in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 721,957 shares of the company's stock, valued at approximately $31,203,000. Capital World Investors owned 0.77% of Scholar Rock as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after buying an additional 269 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Scholar Rock by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock valued at $310,000 after purchasing an additional 379 shares in the last quarter. Amalgamated Bank boosted its position in shares of Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock worth $114,000 after purchasing an additional 620 shares during the period. Global Retirement Partners LLC increased its stake in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after purchasing an additional 1,031 shares during the period. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Scholar Rock news, insider Mo Qatanani sold 68,510 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the sale, the insider now directly owns 111,084 shares in the company, valued at $4,154,541.60. This represents a 38.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Tracey Sacco sold 6,500 shares of Scholar Rock stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the transaction, the insider now owns 71,750 shares of the company's stock, valued at approximately $2,373,490. This trade represents a 8.31 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 250,231 shares of company stock worth $9,056,086. 13.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, Wedbush reaffirmed an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $42.67.

Scholar Rock Price Performance

Scholar Rock stock traded down $1.57 during midday trading on Friday, reaching $32.81. 694,304 shares of the stock traded hands, compared to its average volume of 1,240,686. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The stock's fifty day moving average is $32.77 and its 200-day moving average is $35.60. The stock has a market cap of $3.11 billion, a P/E ratio of -13.96 and a beta of 0.56.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.